Homology Medicines, Inc. (FIXX)
(Delayed Data from NSDQ)
$22.32 USD
+0.63 (2.90%)
Updated May 3, 2019 04:00 PM ET
After-Market: $22.27 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
Q32 Bio Inc. [FIXX]
Reports for Purchase
Showing records 1 - 20 ( 42 total )
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
Price: 12.50
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
1Q23 Results; PKU Gene Editing Program Update Expected Mid-2023; Strong ASGCT Presence Bolsters Confidence in Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
4Q22 Results; Lead PKU Gene Editing Program on Track for Data in Mid-2023; Additional Programs Advancing; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
3Q22 Results; Progress Across the Gene Therapy and Editing Pipeline With Updates Expected Near-Term
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
2Q22 Results; Shifting Focus to PKU Gene Editing Program; Strong Capital Position Pushes Cash Runway to 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
FDA Lifts Clinical Hold on Lead PKU Program as New Immunosuppression Regimen Is Deployed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 5.00
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
1Q22 Results; Extends Cash Runway to 2H24; FDA Clinical Hold Being Addressed; Multiple Program Updates Expected 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
4Q21 Results; Clinical Hold Details On pheNIX Emerge, With Viable Path Forward; Other Pipeline Compounds Advancing
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
Management Q&A; Clinical Hold on Lead pheNIX Program, Including Potential Next Steps; Reducing PT to $20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
Strikes Deal with OXB to Outsource Manufacturing; Receives $130M Non-Dilutive Funding; Pipeline on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
3Q21 Results; Progress on Multiple Fronts; Lead pheNIX Program Phase 2 Update Pushed to Mid-2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 12.50
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
Price: 25.00
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
2Q21 Results; Phase 2 pheNIX PKU Data Expected 2H21; Gene Editing Study Start in PKU on Track for 2H21
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 25.00
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
Multiple Platform Updates; C5 Program Unveiled; pheNIX Trial Expansion Phase Update Expected Late in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 25.00
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
So Little Time, So Many Genes to Fix; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Price: 25.00
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
Transferring Coverage With a Buy and $30 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Price: 75.00
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
2Q20 Update; pheNIX Timeline Negatively Impacted by Pace of Enrollment; Target Lowered to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 25.00
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
Biomarin Widens the Goal Post for PKU Gene Therapy; A Clear Positive for the pheNIX Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 10.00
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
Looking Ahead to Mid-Year pheNIX Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 25.00
Company: Q32 Bio Inc.
Industry: Medical - Generic Drugs
A Dive Into AAV-Induced LFT Abnormalities and Impact on Protein Expression
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Price: 75.00